The Series A round was led by AlbionVC and will support expansion into France and Germany.
"After rapidly growing our team and entering the Spanish market, we’ll now be broadening our focus within Europe, including expansion into France and Germany. This new funding round will enable us to keep evolving and delivering on our vision: we aim to become the world’s premier fintech SaaS platform, giving our clients the ability to create, customise, and launch bank-grade digital finance solutions, enriched by our Marketplace of reputable and trusted partners."
The financing round was led by Barclays and includes participation from BCI Finance.
"This is a great opportunity for Liberis to continue helping SME growth across the globe, especially in such uncertain times that have been brought upon us by the COVID-19 pandemic. This funding will be crucial to supporting our partners in funding their SME customers to close the ever-expanding global funding gap."
Octopus Ventures led the Series B round, which will fund product development and international expansion.
"In a world in which volatility and complexity are increasing and the nature of work and talent are drastically changing, it is critical that organisations develop the capability and capacity to think and act differently when it comes to change and innovation"
The company has raised a fresh tranche of capital from backers including Wealth Club to drive growth across the UK and US.
"This latest round of investment in BibliU, from a hugely experienced group of investors, will only serve to further our mission to provide high-quality, accessible and vital learning resources at an affordable cost."
The Oxford medical technology company secured backing from investors including Mercia and IQ Capital to scale its diagnostic software.
"Following years of research and clinical trials that have shown the impact of our software on the diagnosis of at-risk lung nodules, we’re focused on expanding patient access to this crucial technology and identifying deadly lung cancer faster in more at-risk people. The funding will also boost our research and development with world-leading institutions and partners to progress further innovation."
.png)
